nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—PIP4K2C—Erlotinib—pancreatic cancer	0.113	0.165	CbGbCtD
Imatinib—HIPK4—Erlotinib—pancreatic cancer	0.0573	0.0839	CbGbCtD
Imatinib—ABL2—Erlotinib—pancreatic cancer	0.0515	0.0754	CbGbCtD
Imatinib—NTRK1—Sunitinib—pancreatic cancer	0.0494	0.0724	CbGbCtD
Imatinib—HIPK4—Sunitinib—pancreatic cancer	0.0378	0.0553	CbGbCtD
Imatinib—ABL1—Erlotinib—pancreatic cancer	0.0372	0.0545	CbGbCtD
Imatinib—KIT—Sunitinib—pancreatic cancer	0.0339	0.0497	CbGbCtD
Imatinib—CSF1R—Sunitinib—pancreatic cancer	0.0339	0.0497	CbGbCtD
Imatinib—PDGFRA—Sunitinib—pancreatic cancer	0.0339	0.0497	CbGbCtD
Imatinib—PDGFRB—Sunitinib—pancreatic cancer	0.0309	0.0452	CbGbCtD
Imatinib—ORM1—Erlotinib—pancreatic cancer	0.0139	0.0204	CbGbCtD
Imatinib—ABCG2—Tamoxifen—pancreatic cancer	0.01	0.0146	CbGbCtD
Imatinib—ABCG2—Erlotinib—pancreatic cancer	0.00851	0.0125	CbGbCtD
Imatinib—ABCG2—Irinotecan—pancreatic cancer	0.00768	0.0112	CbGbCtD
Imatinib—CYP3A7—Tamoxifen—pancreatic cancer	0.00739	0.0108	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Tamoxifen—pancreatic cancer	0.00739	0.0108	CbGbCtD
Imatinib—ABCG2—Fluorouracil—pancreatic cancer	0.00737	0.0108	CbGbCtD
Imatinib—ALB—Erlotinib—pancreatic cancer	0.00586	0.00858	CbGbCtD
Imatinib—CYP3A7—Irinotecan—pancreatic cancer	0.00567	0.0083	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Irinotecan—pancreatic cancer	0.00567	0.0083	CbGbCtD
Imatinib—ABCG2—Docetaxel—pancreatic cancer	0.00563	0.00824	CbGbCtD
Imatinib—ABCG2—Sunitinib—pancreatic cancer	0.0056	0.0082	CbGbCtD
Imatinib—CYP3A5—Tamoxifen—pancreatic cancer	0.00554	0.00811	CbGbCtD
Imatinib—ALB—Irinotecan—pancreatic cancer	0.0053	0.00775	CbGbCtD
Imatinib—CYP1A2—Dacarbazine—pancreatic cancer	0.00519	0.00759	CbGbCtD
Imatinib—ALB—Fluorouracil—pancreatic cancer	0.00508	0.00744	CbGbCtD
Imatinib—CYP3A5—Erlotinib—pancreatic cancer	0.00471	0.0069	CbGbCtD
Imatinib—CYP2C19—Tamoxifen—pancreatic cancer	0.00447	0.00654	CbGbCtD
Imatinib—CYP3A5—Irinotecan—pancreatic cancer	0.00426	0.00623	CbGbCtD
Imatinib—ABCG2—Doxorubicin—pancreatic cancer	0.0042	0.00614	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Docetaxel—pancreatic cancer	0.00416	0.00609	CbGbCtD
Imatinib—CYP3A7—Docetaxel—pancreatic cancer	0.00416	0.00609	CbGbCtD
Imatinib—CYP3A7—Sunitinib—pancreatic cancer	0.00414	0.00606	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Sunitinib—pancreatic cancer	0.00414	0.00606	CbGbCtD
Imatinib—CYP1A2—Tamoxifen—pancreatic cancer	0.00413	0.00604	CbGbCtD
Imatinib—ORM1—bile—pancreatic cancer	0.00387	0.107	CbGeAlD
Imatinib—CYP2C9—Tamoxifen—pancreatic cancer	0.00372	0.00544	CbGbCtD
Imatinib—ABCB1—Tamoxifen—pancreatic cancer	0.00361	0.00528	CbGbCtD
Imatinib—CYP1A2—Erlotinib—pancreatic cancer	0.00351	0.00513	CbGbCtD
Imatinib—CYP2D6—Tamoxifen—pancreatic cancer	0.0034	0.00498	CbGbCtD
Imatinib—CYP3A5—Docetaxel—pancreatic cancer	0.00312	0.00457	CbGbCtD
Imatinib—ABCB1—Gemcitabine—pancreatic cancer	0.00311	0.00455	CbGbCtD
Imatinib—CYP3A5—Sunitinib—pancreatic cancer	0.0031	0.00454	CbGbCtD
Imatinib—ABCB1—Erlotinib—pancreatic cancer	0.00307	0.00449	CbGbCtD
Imatinib—CYP1A2—Fluorouracil—pancreatic cancer	0.00304	0.00445	CbGbCtD
Imatinib—CYP2D6—Erlotinib—pancreatic cancer	0.00289	0.00423	CbGbCtD
Imatinib—ABCB1—Irinotecan—pancreatic cancer	0.00277	0.00405	CbGbCtD
Imatinib—CYP2C9—Fluorouracil—pancreatic cancer	0.00274	0.00401	CbGbCtD
Imatinib—ABCA3—islet of Langerhans—pancreatic cancer	0.0023	0.0634	CbGeAlD
Imatinib—CYP3A4—Tamoxifen—pancreatic cancer	0.00216	0.00316	CbGbCtD
Imatinib—DDR1—islet of Langerhans—pancreatic cancer	0.00213	0.0585	CbGeAlD
Imatinib—ABCB1—Docetaxel—pancreatic cancer	0.00203	0.00297	CbGbCtD
Imatinib—ABCB1—Sunitinib—pancreatic cancer	0.00202	0.00296	CbGbCtD
Imatinib—CYP3A4—Erlotinib—pancreatic cancer	0.00184	0.00269	CbGbCtD
Imatinib—CA9—gall bladder—pancreatic cancer	0.00183	0.0504	CbGeAlD
Imatinib—CYP3A4—Irinotecan—pancreatic cancer	0.00166	0.00243	CbGbCtD
Imatinib—Ponatinib—SRC—pancreatic cancer	0.0016	0.516	CrCbGaD
Imatinib—ABCB1—Doxorubicin—pancreatic cancer	0.00151	0.00221	CbGbCtD
Imatinib—Ponatinib—KDR—pancreatic cancer	0.0015	0.484	CrCbGaD
Imatinib—DDR1—pancreas—pancreatic cancer	0.00149	0.0412	CbGeAlD
Imatinib—PDGFRA—gall bladder—pancreatic cancer	0.00147	0.0404	CbGeAlD
Imatinib—CYP2D6—Doxorubicin—pancreatic cancer	0.00143	0.00209	CbGbCtD
Imatinib—PIP4K2C—islet of Langerhans—pancreatic cancer	0.00131	0.0361	CbGeAlD
Imatinib—CYP3A4—Docetaxel—pancreatic cancer	0.00122	0.00178	CbGbCtD
Imatinib—CYP3A4—Sunitinib—pancreatic cancer	0.00121	0.00177	CbGbCtD
Imatinib—CA9—islet of Langerhans—pancreatic cancer	0.0012	0.033	CbGeAlD
Imatinib—ABL1—Topotecan—Irinotecan—pancreatic cancer	0.00118	0.424	CbGdCrCtD
Imatinib—KIT—gall bladder—pancreatic cancer	0.00117	0.0323	CbGeAlD
Imatinib—PDGFRB—gall bladder—pancreatic cancer	0.00114	0.0315	CbGeAlD
Imatinib—ORM1—gall bladder—pancreatic cancer	0.00107	0.0296	CbGeAlD
Imatinib—NQO2—islet of Langerhans—pancreatic cancer	0.000963	0.0265	CbGeAlD
Imatinib—ALB—gall bladder—pancreatic cancer	0.000941	0.0259	CbGeAlD
Imatinib—PIP4K2C—pancreas—pancreatic cancer	0.000922	0.0254	CbGeAlD
Imatinib—CYP3A4—Doxorubicin—pancreatic cancer	0.000907	0.00133	CbGbCtD
Imatinib—CA7—digestive system—pancreatic cancer	0.00082	0.0226	CbGeAlD
Imatinib—PDGFRB—islet of Langerhans—pancreatic cancer	0.00075	0.0207	CbGeAlD
Imatinib—CA9—digestive system—pancreatic cancer	0.00072	0.0198	CbGeAlD
Imatinib—CA2—gall bladder—pancreatic cancer	0.000695	0.0191	CbGeAlD
Imatinib—NQO2—pancreas—pancreatic cancer	0.000677	0.0187	CbGeAlD
Imatinib—ABL1—islet of Langerhans—pancreatic cancer	0.000669	0.0184	CbGeAlD
Imatinib—PDGFRA—digestive system—pancreatic cancer	0.000577	0.0159	CbGeAlD
Imatinib—SLC22A2—digestive system—pancreatic cancer	0.000548	0.0151	CbGeAlD
Imatinib—KIT—pancreas—pancreatic cancer	0.00054	0.0149	CbGeAlD
Imatinib—CA12—digestive system—pancreatic cancer	0.000532	0.0147	CbGeAlD
Imatinib—PDGFRB—pancreas—pancreatic cancer	0.000527	0.0145	CbGeAlD
Imatinib—CSF1R—digestive system—pancreatic cancer	0.000508	0.014	CbGeAlD
Imatinib—CA1—pancreas—pancreatic cancer	0.000494	0.0136	CbGeAlD
Imatinib—ABL1—pancreas—pancreatic cancer	0.00047	0.013	CbGeAlD
Imatinib—SLC47A1—digestive system—pancreatic cancer	0.000464	0.0128	CbGeAlD
Imatinib—KIT—digestive system—pancreatic cancer	0.000461	0.0127	CbGeAlD
Imatinib—CA2—islet of Langerhans—pancreatic cancer	0.000455	0.0125	CbGeAlD
Imatinib—PDGFRB—digestive system—pancreatic cancer	0.00045	0.0124	CbGeAlD
Imatinib—CA1—digestive system—pancreatic cancer	0.000422	0.0116	CbGeAlD
Imatinib—ABL1—digestive system—pancreatic cancer	0.000401	0.0111	CbGeAlD
Imatinib—CYP3A5—islet of Langerhans—pancreatic cancer	0.000391	0.0108	CbGeAlD
Imatinib—CA2—pancreas—pancreatic cancer	0.00032	0.00882	CbGeAlD
Imatinib—CYP2C19—digestive system—pancreatic cancer	0.000298	0.00822	CbGeAlD
Imatinib—ABL1—Idarubicin—Epirubicin—pancreatic cancer	0.000276	0.0997	CbGdCrCtD
Imatinib—ABL1—Doxorubicin—Epirubicin—pancreatic cancer	0.000276	0.0997	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Epirubicin—pancreatic cancer	0.000276	0.0997	CbGdCrCtD
Imatinib—CYP3A5—pancreas—pancreatic cancer	0.000275	0.00758	CbGeAlD
Imatinib—CA2—digestive system—pancreatic cancer	0.000273	0.00753	CbGeAlD
Imatinib—ABL1—Epirubicin—Doxorubicin—pancreatic cancer	0.000256	0.0922	CbGdCrCtD
Imatinib—ABL1—Idarubicin—Doxorubicin—pancreatic cancer	0.000256	0.0922	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Doxorubicin—pancreatic cancer	0.000256	0.0922	CbGdCrCtD
Imatinib—CYP1A2—digestive system—pancreatic cancer	0.000244	0.00671	CbGeAlD
Imatinib—CYP3A5—digestive system—pancreatic cancer	0.000235	0.00647	CbGeAlD
Imatinib—CYP2C9—digestive system—pancreatic cancer	0.000231	0.00637	CbGeAlD
Imatinib—PTGS1—digestive system—pancreatic cancer	0.000211	0.00582	CbGeAlD
Imatinib—ABCB1—islet of Langerhans—pancreatic cancer	0.000208	0.00573	CbGeAlD
Imatinib—CYP3A4—digestive system—pancreatic cancer	0.000176	0.00486	CbGeAlD
Imatinib—CYP2D6—digestive system—pancreatic cancer	0.000174	0.00478	CbGeAlD
Imatinib—ABCB1—pancreas—pancreatic cancer	0.000146	0.00403	CbGeAlD
Imatinib—ABCB1—digestive system—pancreatic cancer	0.000125	0.00344	CbGeAlD
Imatinib—Hepatobiliary disease—Epirubicin—pancreatic cancer	4.86e-05	0.000279	CcSEcCtD
Imatinib—Oedema—Docetaxel—pancreatic cancer	4.86e-05	0.000279	CcSEcCtD
Imatinib—Anaphylactic shock—Docetaxel—pancreatic cancer	4.86e-05	0.000279	CcSEcCtD
Imatinib—Weight increased—Doxorubicin—pancreatic cancer	4.86e-05	0.000279	CcSEcCtD
Imatinib—Epistaxis—Epirubicin—pancreatic cancer	4.85e-05	0.000278	CcSEcCtD
Imatinib—Pruritus—Gemcitabine—pancreatic cancer	4.85e-05	0.000278	CcSEcCtD
Imatinib—Infection—Docetaxel—pancreatic cancer	4.83e-05	0.000277	CcSEcCtD
Imatinib—Weight decreased—Doxorubicin—pancreatic cancer	4.83e-05	0.000277	CcSEcCtD
Imatinib—Sinusitis—Epirubicin—pancreatic cancer	4.82e-05	0.000277	CcSEcCtD
Imatinib—Hyperglycaemia—Doxorubicin—pancreatic cancer	4.81e-05	0.000276	CcSEcCtD
Imatinib—Diarrhoea—Irinotecan—pancreatic cancer	4.81e-05	0.000276	CcSEcCtD
Imatinib—Agranulocytosis—Epirubicin—pancreatic cancer	4.8e-05	0.000275	CcSEcCtD
Imatinib—Pneumonia—Doxorubicin—pancreatic cancer	4.79e-05	0.000275	CcSEcCtD
Imatinib—Shock—Docetaxel—pancreatic cancer	4.78e-05	0.000274	CcSEcCtD
Imatinib—Nervous system disorder—Docetaxel—pancreatic cancer	4.77e-05	0.000274	CcSEcCtD
Imatinib—Pruritus—Fluorouracil—pancreatic cancer	4.77e-05	0.000273	CcSEcCtD
Imatinib—Thrombocytopenia—Docetaxel—pancreatic cancer	4.76e-05	0.000273	CcSEcCtD
Imatinib—Infestation NOS—Doxorubicin—pancreatic cancer	4.76e-05	0.000273	CcSEcCtD
Imatinib—Infestation—Doxorubicin—pancreatic cancer	4.76e-05	0.000273	CcSEcCtD
Imatinib—Tachycardia—Docetaxel—pancreatic cancer	4.75e-05	0.000272	CcSEcCtD
Imatinib—Skin disorder—Docetaxel—pancreatic cancer	4.72e-05	0.000271	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	4.72e-05	0.000271	CcSEcCtD
Imatinib—Diarrhoea—Gemcitabine—pancreatic cancer	4.69e-05	0.000269	CcSEcCtD
Imatinib—Renal failure—Doxorubicin—pancreatic cancer	4.68e-05	0.000268	CcSEcCtD
Imatinib—Neuropathy peripheral—Doxorubicin—pancreatic cancer	4.66e-05	0.000268	CcSEcCtD
Imatinib—Dizziness—Irinotecan—pancreatic cancer	4.65e-05	0.000267	CcSEcCtD
Imatinib—Haemoglobin—Epirubicin—pancreatic cancer	4.64e-05	0.000266	CcSEcCtD
Imatinib—Stomatitis—Doxorubicin—pancreatic cancer	4.64e-05	0.000266	CcSEcCtD
Imatinib—Jaundice—Doxorubicin—pancreatic cancer	4.64e-05	0.000266	CcSEcCtD
Imatinib—Anorexia—Docetaxel—pancreatic cancer	4.64e-05	0.000266	CcSEcCtD
Imatinib—Rhinitis—Epirubicin—pancreatic cancer	4.63e-05	0.000265	CcSEcCtD
Imatinib—Urinary tract infection—Doxorubicin—pancreatic cancer	4.63e-05	0.000265	CcSEcCtD
Imatinib—Conjunctivitis—Doxorubicin—pancreatic cancer	4.63e-05	0.000265	CcSEcCtD
Imatinib—Haemorrhage—Epirubicin—pancreatic cancer	4.62e-05	0.000265	CcSEcCtD
Imatinib—Hepatitis—Epirubicin—pancreatic cancer	4.62e-05	0.000265	CcSEcCtD
Imatinib—Diarrhoea—Fluorouracil—pancreatic cancer	4.61e-05	0.000264	CcSEcCtD
Imatinib—Hypoaesthesia—Epirubicin—pancreatic cancer	4.59e-05	0.000263	CcSEcCtD
Imatinib—Pharyngitis—Epirubicin—pancreatic cancer	4.58e-05	0.000263	CcSEcCtD
Imatinib—Sweating—Doxorubicin—pancreatic cancer	4.56e-05	0.000262	CcSEcCtD
Imatinib—Urinary tract disorder—Epirubicin—pancreatic cancer	4.56e-05	0.000262	CcSEcCtD
Imatinib—Oedema peripheral—Epirubicin—pancreatic cancer	4.55e-05	0.000261	CcSEcCtD
Imatinib—Hypotension—Docetaxel—pancreatic cancer	4.54e-05	0.000261	CcSEcCtD
Imatinib—Haematuria—Doxorubicin—pancreatic cancer	4.54e-05	0.00026	CcSEcCtD
Imatinib—Connective tissue disorder—Epirubicin—pancreatic cancer	4.54e-05	0.00026	CcSEcCtD
Imatinib—Urethral disorder—Epirubicin—pancreatic cancer	4.53e-05	0.00026	CcSEcCtD
Imatinib—Hepatobiliary disease—Doxorubicin—pancreatic cancer	4.5e-05	0.000258	CcSEcCtD
Imatinib—Epistaxis—Doxorubicin—pancreatic cancer	4.49e-05	0.000257	CcSEcCtD
Imatinib—Vomiting—Irinotecan—pancreatic cancer	4.47e-05	0.000257	CcSEcCtD
Imatinib—Sinusitis—Doxorubicin—pancreatic cancer	4.46e-05	0.000256	CcSEcCtD
Imatinib—Dizziness—Fluorouracil—pancreatic cancer	4.46e-05	0.000256	CcSEcCtD
Imatinib—Agranulocytosis—Doxorubicin—pancreatic cancer	4.44e-05	0.000255	CcSEcCtD
Imatinib—Rash—Irinotecan—pancreatic cancer	4.44e-05	0.000254	CcSEcCtD
Imatinib—Dermatitis—Irinotecan—pancreatic cancer	4.43e-05	0.000254	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	4.43e-05	0.000254	CcSEcCtD
Imatinib—Headache—Irinotecan—pancreatic cancer	4.41e-05	0.000253	CcSEcCtD
Imatinib—Insomnia—Docetaxel—pancreatic cancer	4.4e-05	0.000252	CcSEcCtD
Imatinib—Paraesthesia—Docetaxel—pancreatic cancer	4.37e-05	0.00025	CcSEcCtD
Imatinib—Erythema multiforme—Epirubicin—pancreatic cancer	4.36e-05	0.00025	CcSEcCtD
Imatinib—Vomiting—Gemcitabine—pancreatic cancer	4.36e-05	0.00025	CcSEcCtD
Imatinib—Dyspnoea—Docetaxel—pancreatic cancer	4.34e-05	0.000249	CcSEcCtD
Imatinib—Somnolence—Docetaxel—pancreatic cancer	4.32e-05	0.000248	CcSEcCtD
Imatinib—Rash—Gemcitabine—pancreatic cancer	4.32e-05	0.000248	CcSEcCtD
Imatinib—Dermatitis—Gemcitabine—pancreatic cancer	4.32e-05	0.000248	CcSEcCtD
Imatinib—Eye disorder—Epirubicin—pancreatic cancer	4.31e-05	0.000247	CcSEcCtD
Imatinib—Tinnitus—Epirubicin—pancreatic cancer	4.3e-05	0.000247	CcSEcCtD
Imatinib—Haemoglobin—Doxorubicin—pancreatic cancer	4.29e-05	0.000246	CcSEcCtD
Imatinib—Headache—Gemcitabine—pancreatic cancer	4.29e-05	0.000246	CcSEcCtD
Imatinib—Flushing—Epirubicin—pancreatic cancer	4.28e-05	0.000246	CcSEcCtD
Imatinib—Cardiac disorder—Epirubicin—pancreatic cancer	4.28e-05	0.000246	CcSEcCtD
Imatinib—Vomiting—Fluorouracil—pancreatic cancer	4.28e-05	0.000246	CcSEcCtD
Imatinib—Rhinitis—Doxorubicin—pancreatic cancer	4.28e-05	0.000246	CcSEcCtD
Imatinib—Dyspepsia—Docetaxel—pancreatic cancer	4.28e-05	0.000246	CcSEcCtD
Imatinib—Haemorrhage—Doxorubicin—pancreatic cancer	4.27e-05	0.000245	CcSEcCtD
Imatinib—Hepatitis—Doxorubicin—pancreatic cancer	4.27e-05	0.000245	CcSEcCtD
Imatinib—Hypoaesthesia—Doxorubicin—pancreatic cancer	4.25e-05	0.000244	CcSEcCtD
Imatinib—Rash—Fluorouracil—pancreatic cancer	4.25e-05	0.000244	CcSEcCtD
Imatinib—Dermatitis—Fluorouracil—pancreatic cancer	4.24e-05	0.000243	CcSEcCtD
Imatinib—Pharyngitis—Doxorubicin—pancreatic cancer	4.24e-05	0.000243	CcSEcCtD
Imatinib—Decreased appetite—Docetaxel—pancreatic cancer	4.23e-05	0.000242	CcSEcCtD
Imatinib—Headache—Fluorouracil—pancreatic cancer	4.22e-05	0.000242	CcSEcCtD
Imatinib—Urinary tract disorder—Doxorubicin—pancreatic cancer	4.22e-05	0.000242	CcSEcCtD
Imatinib—Oedema peripheral—Doxorubicin—pancreatic cancer	4.21e-05	0.000241	CcSEcCtD
Imatinib—Gastrointestinal disorder—Docetaxel—pancreatic cancer	4.2e-05	0.000241	CcSEcCtD
Imatinib—Connective tissue disorder—Doxorubicin—pancreatic cancer	4.2e-05	0.000241	CcSEcCtD
Imatinib—Fatigue—Docetaxel—pancreatic cancer	4.19e-05	0.00024	CcSEcCtD
Imatinib—Angiopathy—Epirubicin—pancreatic cancer	4.19e-05	0.00024	CcSEcCtD
Imatinib—Urethral disorder—Doxorubicin—pancreatic cancer	4.19e-05	0.00024	CcSEcCtD
Imatinib—Nausea—Irinotecan—pancreatic cancer	4.18e-05	0.00024	CcSEcCtD
Imatinib—Immune system disorder—Epirubicin—pancreatic cancer	4.17e-05	0.000239	CcSEcCtD
Imatinib—Mediastinal disorder—Epirubicin—pancreatic cancer	4.16e-05	0.000239	CcSEcCtD
Imatinib—Pain—Docetaxel—pancreatic cancer	4.16e-05	0.000239	CcSEcCtD
Imatinib—Constipation—Docetaxel—pancreatic cancer	4.16e-05	0.000239	CcSEcCtD
Imatinib—Chills—Epirubicin—pancreatic cancer	4.14e-05	0.000238	CcSEcCtD
Imatinib—Arrhythmia—Epirubicin—pancreatic cancer	4.12e-05	0.000237	CcSEcCtD
Imatinib—Alopecia—Epirubicin—pancreatic cancer	4.08e-05	0.000234	CcSEcCtD
Imatinib—Nausea—Gemcitabine—pancreatic cancer	4.07e-05	0.000233	CcSEcCtD
Imatinib—Mental disorder—Epirubicin—pancreatic cancer	4.04e-05	0.000232	CcSEcCtD
Imatinib—Erythema multiforme—Doxorubicin—pancreatic cancer	4.04e-05	0.000232	CcSEcCtD
Imatinib—Erythema—Epirubicin—pancreatic cancer	4.02e-05	0.000231	CcSEcCtD
Imatinib—Malnutrition—Epirubicin—pancreatic cancer	4.02e-05	0.000231	CcSEcCtD
Imatinib—Feeling abnormal—Docetaxel—pancreatic cancer	4.01e-05	0.00023	CcSEcCtD
Imatinib—Nausea—Fluorouracil—pancreatic cancer	4e-05	0.00023	CcSEcCtD
Imatinib—Eye disorder—Doxorubicin—pancreatic cancer	3.99e-05	0.000229	CcSEcCtD
Imatinib—Tinnitus—Doxorubicin—pancreatic cancer	3.98e-05	0.000228	CcSEcCtD
Imatinib—Gastrointestinal pain—Docetaxel—pancreatic cancer	3.98e-05	0.000228	CcSEcCtD
Imatinib—Flushing—Doxorubicin—pancreatic cancer	3.96e-05	0.000227	CcSEcCtD
Imatinib—Cardiac disorder—Doxorubicin—pancreatic cancer	3.96e-05	0.000227	CcSEcCtD
Imatinib—Flatulence—Epirubicin—pancreatic cancer	3.96e-05	0.000227	CcSEcCtD
Imatinib—Dysgeusia—Epirubicin—pancreatic cancer	3.94e-05	0.000226	CcSEcCtD
Imatinib—Back pain—Epirubicin—pancreatic cancer	3.89e-05	0.000223	CcSEcCtD
Imatinib—Angiopathy—Doxorubicin—pancreatic cancer	3.88e-05	0.000222	CcSEcCtD
Imatinib—Muscle spasms—Epirubicin—pancreatic cancer	3.86e-05	0.000222	CcSEcCtD
Imatinib—Immune system disorder—Doxorubicin—pancreatic cancer	3.86e-05	0.000221	CcSEcCtD
Imatinib—Mediastinal disorder—Doxorubicin—pancreatic cancer	3.85e-05	0.000221	CcSEcCtD
Imatinib—Abdominal pain—Docetaxel—pancreatic cancer	3.84e-05	0.00022	CcSEcCtD
Imatinib—Body temperature increased—Docetaxel—pancreatic cancer	3.84e-05	0.00022	CcSEcCtD
Imatinib—Chills—Doxorubicin—pancreatic cancer	3.83e-05	0.00022	CcSEcCtD
Imatinib—Arrhythmia—Doxorubicin—pancreatic cancer	3.82e-05	0.000219	CcSEcCtD
Imatinib—Vision blurred—Epirubicin—pancreatic cancer	3.79e-05	0.000217	CcSEcCtD
Imatinib—Alopecia—Doxorubicin—pancreatic cancer	3.77e-05	0.000217	CcSEcCtD
Imatinib—Mental disorder—Doxorubicin—pancreatic cancer	3.74e-05	0.000215	CcSEcCtD
Imatinib—Ill-defined disorder—Epirubicin—pancreatic cancer	3.73e-05	0.000214	CcSEcCtD
Imatinib—Malnutrition—Doxorubicin—pancreatic cancer	3.72e-05	0.000213	CcSEcCtD
Imatinib—Erythema—Doxorubicin—pancreatic cancer	3.72e-05	0.000213	CcSEcCtD
Imatinib—Anaemia—Epirubicin—pancreatic cancer	3.71e-05	0.000213	CcSEcCtD
Imatinib—Flatulence—Doxorubicin—pancreatic cancer	3.66e-05	0.00021	CcSEcCtD
Imatinib—Dysgeusia—Doxorubicin—pancreatic cancer	3.64e-05	0.000209	CcSEcCtD
Imatinib—Malaise—Epirubicin—pancreatic cancer	3.62e-05	0.000208	CcSEcCtD
Imatinib—Vertigo—Epirubicin—pancreatic cancer	3.61e-05	0.000207	CcSEcCtD
Imatinib—Syncope—Epirubicin—pancreatic cancer	3.6e-05	0.000207	CcSEcCtD
Imatinib—Leukopenia—Epirubicin—pancreatic cancer	3.6e-05	0.000206	CcSEcCtD
Imatinib—Back pain—Doxorubicin—pancreatic cancer	3.6e-05	0.000206	CcSEcCtD
Imatinib—Hypersensitivity—Docetaxel—pancreatic cancer	3.58e-05	0.000205	CcSEcCtD
Imatinib—Muscle spasms—Doxorubicin—pancreatic cancer	3.58e-05	0.000205	CcSEcCtD
Imatinib—Palpitations—Epirubicin—pancreatic cancer	3.55e-05	0.000204	CcSEcCtD
Imatinib—Loss of consciousness—Epirubicin—pancreatic cancer	3.53e-05	0.000203	CcSEcCtD
Imatinib—Cough—Epirubicin—pancreatic cancer	3.51e-05	0.000201	CcSEcCtD
Imatinib—Vision blurred—Doxorubicin—pancreatic cancer	3.5e-05	0.000201	CcSEcCtD
Imatinib—Asthenia—Docetaxel—pancreatic cancer	3.49e-05	0.0002	CcSEcCtD
Imatinib—Convulsion—Epirubicin—pancreatic cancer	3.48e-05	0.0002	CcSEcCtD
Imatinib—Hypertension—Epirubicin—pancreatic cancer	3.47e-05	0.000199	CcSEcCtD
Imatinib—Ill-defined disorder—Doxorubicin—pancreatic cancer	3.45e-05	0.000198	CcSEcCtD
Imatinib—Pruritus—Docetaxel—pancreatic cancer	3.44e-05	0.000197	CcSEcCtD
Imatinib—Anaemia—Doxorubicin—pancreatic cancer	3.44e-05	0.000197	CcSEcCtD
Imatinib—Chest pain—Epirubicin—pancreatic cancer	3.42e-05	0.000196	CcSEcCtD
Imatinib—Arthralgia—Epirubicin—pancreatic cancer	3.42e-05	0.000196	CcSEcCtD
Imatinib—Myalgia—Epirubicin—pancreatic cancer	3.42e-05	0.000196	CcSEcCtD
Imatinib—Anxiety—Epirubicin—pancreatic cancer	3.41e-05	0.000196	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	3.4e-05	0.000195	CcSEcCtD
Imatinib—Discomfort—Epirubicin—pancreatic cancer	3.38e-05	0.000194	CcSEcCtD
Imatinib—Malaise—Doxorubicin—pancreatic cancer	3.35e-05	0.000192	CcSEcCtD
Imatinib—Dry mouth—Epirubicin—pancreatic cancer	3.35e-05	0.000192	CcSEcCtD
Imatinib—Vertigo—Doxorubicin—pancreatic cancer	3.34e-05	0.000192	CcSEcCtD
Imatinib—Syncope—Doxorubicin—pancreatic cancer	3.33e-05	0.000191	CcSEcCtD
Imatinib—Leukopenia—Doxorubicin—pancreatic cancer	3.33e-05	0.000191	CcSEcCtD
Imatinib—Diarrhoea—Docetaxel—pancreatic cancer	3.33e-05	0.000191	CcSEcCtD
Imatinib—Confusional state—Epirubicin—pancreatic cancer	3.31e-05	0.00019	CcSEcCtD
Imatinib—Palpitations—Doxorubicin—pancreatic cancer	3.29e-05	0.000188	CcSEcCtD
Imatinib—Oedema—Epirubicin—pancreatic cancer	3.28e-05	0.000188	CcSEcCtD
Imatinib—Anaphylactic shock—Epirubicin—pancreatic cancer	3.28e-05	0.000188	CcSEcCtD
Imatinib—Loss of consciousness—Doxorubicin—pancreatic cancer	3.27e-05	0.000187	CcSEcCtD
Imatinib—Infection—Epirubicin—pancreatic cancer	3.26e-05	0.000187	CcSEcCtD
Imatinib—Cough—Doxorubicin—pancreatic cancer	3.24e-05	0.000186	CcSEcCtD
Imatinib—Shock—Epirubicin—pancreatic cancer	3.23e-05	0.000185	CcSEcCtD
Imatinib—Convulsion—Doxorubicin—pancreatic cancer	3.22e-05	0.000185	CcSEcCtD
Imatinib—Nervous system disorder—Epirubicin—pancreatic cancer	3.22e-05	0.000184	CcSEcCtD
Imatinib—Dizziness—Docetaxel—pancreatic cancer	3.22e-05	0.000184	CcSEcCtD
Imatinib—Thrombocytopenia—Epirubicin—pancreatic cancer	3.21e-05	0.000184	CcSEcCtD
Imatinib—Hypertension—Doxorubicin—pancreatic cancer	3.21e-05	0.000184	CcSEcCtD
Imatinib—Tachycardia—Epirubicin—pancreatic cancer	3.2e-05	0.000184	CcSEcCtD
Imatinib—Skin disorder—Epirubicin—pancreatic cancer	3.19e-05	0.000183	CcSEcCtD
Imatinib—Hyperhidrosis—Epirubicin—pancreatic cancer	3.17e-05	0.000182	CcSEcCtD
Imatinib—Chest pain—Doxorubicin—pancreatic cancer	3.17e-05	0.000182	CcSEcCtD
Imatinib—Arthralgia—Doxorubicin—pancreatic cancer	3.17e-05	0.000182	CcSEcCtD
Imatinib—Myalgia—Doxorubicin—pancreatic cancer	3.17e-05	0.000182	CcSEcCtD
Imatinib—Anxiety—Doxorubicin—pancreatic cancer	3.15e-05	0.000181	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	3.14e-05	0.00018	CcSEcCtD
Imatinib—Discomfort—Doxorubicin—pancreatic cancer	3.13e-05	0.000179	CcSEcCtD
Imatinib—Anorexia—Epirubicin—pancreatic cancer	3.13e-05	0.000179	CcSEcCtD
Imatinib—Dry mouth—Doxorubicin—pancreatic cancer	3.1e-05	0.000178	CcSEcCtD
Imatinib—Vomiting—Docetaxel—pancreatic cancer	3.09e-05	0.000177	CcSEcCtD
Imatinib—Rash—Docetaxel—pancreatic cancer	3.07e-05	0.000176	CcSEcCtD
Imatinib—Hypotension—Epirubicin—pancreatic cancer	3.06e-05	0.000176	CcSEcCtD
Imatinib—Dermatitis—Docetaxel—pancreatic cancer	3.06e-05	0.000176	CcSEcCtD
Imatinib—Confusional state—Doxorubicin—pancreatic cancer	3.06e-05	0.000176	CcSEcCtD
Imatinib—Headache—Docetaxel—pancreatic cancer	3.05e-05	0.000175	CcSEcCtD
Imatinib—Oedema—Doxorubicin—pancreatic cancer	3.03e-05	0.000174	CcSEcCtD
Imatinib—Anaphylactic shock—Doxorubicin—pancreatic cancer	3.03e-05	0.000174	CcSEcCtD
Imatinib—Infection—Doxorubicin—pancreatic cancer	3.01e-05	0.000173	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	2.99e-05	0.000171	CcSEcCtD
Imatinib—Shock—Doxorubicin—pancreatic cancer	2.99e-05	0.000171	CcSEcCtD
Imatinib—Nervous system disorder—Doxorubicin—pancreatic cancer	2.98e-05	0.000171	CcSEcCtD
Imatinib—Thrombocytopenia—Doxorubicin—pancreatic cancer	2.97e-05	0.00017	CcSEcCtD
Imatinib—Insomnia—Epirubicin—pancreatic cancer	2.97e-05	0.00017	CcSEcCtD
Imatinib—Tachycardia—Doxorubicin—pancreatic cancer	2.96e-05	0.00017	CcSEcCtD
Imatinib—Skin disorder—Doxorubicin—pancreatic cancer	2.95e-05	0.000169	CcSEcCtD
Imatinib—Paraesthesia—Epirubicin—pancreatic cancer	2.95e-05	0.000169	CcSEcCtD
Imatinib—Hyperhidrosis—Doxorubicin—pancreatic cancer	2.93e-05	0.000168	CcSEcCtD
Imatinib—Dyspnoea—Epirubicin—pancreatic cancer	2.92e-05	0.000168	CcSEcCtD
Imatinib—Somnolence—Epirubicin—pancreatic cancer	2.92e-05	0.000167	CcSEcCtD
Imatinib—Anorexia—Doxorubicin—pancreatic cancer	2.89e-05	0.000166	CcSEcCtD
Imatinib—Nausea—Docetaxel—pancreatic cancer	2.89e-05	0.000166	CcSEcCtD
Imatinib—Dyspepsia—Epirubicin—pancreatic cancer	2.89e-05	0.000166	CcSEcCtD
Imatinib—Decreased appetite—Epirubicin—pancreatic cancer	2.85e-05	0.000164	CcSEcCtD
Imatinib—Hypotension—Doxorubicin—pancreatic cancer	2.84e-05	0.000163	CcSEcCtD
Imatinib—Gastrointestinal disorder—Epirubicin—pancreatic cancer	2.83e-05	0.000162	CcSEcCtD
Imatinib—Fatigue—Epirubicin—pancreatic cancer	2.83e-05	0.000162	CcSEcCtD
Imatinib—Constipation—Epirubicin—pancreatic cancer	2.8e-05	0.000161	CcSEcCtD
Imatinib—Pain—Epirubicin—pancreatic cancer	2.8e-05	0.000161	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	2.76e-05	0.000159	CcSEcCtD
Imatinib—Insomnia—Doxorubicin—pancreatic cancer	2.74e-05	0.000157	CcSEcCtD
Imatinib—Paraesthesia—Doxorubicin—pancreatic cancer	2.73e-05	0.000156	CcSEcCtD
Imatinib—Dyspnoea—Doxorubicin—pancreatic cancer	2.71e-05	0.000155	CcSEcCtD
Imatinib—Feeling abnormal—Epirubicin—pancreatic cancer	2.7e-05	0.000155	CcSEcCtD
Imatinib—Somnolence—Doxorubicin—pancreatic cancer	2.7e-05	0.000155	CcSEcCtD
Imatinib—Gastrointestinal pain—Epirubicin—pancreatic cancer	2.68e-05	0.000154	CcSEcCtD
Imatinib—Dyspepsia—Doxorubicin—pancreatic cancer	2.67e-05	0.000153	CcSEcCtD
Imatinib—Decreased appetite—Doxorubicin—pancreatic cancer	2.64e-05	0.000151	CcSEcCtD
Imatinib—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	2.62e-05	0.00015	CcSEcCtD
Imatinib—Fatigue—Doxorubicin—pancreatic cancer	2.62e-05	0.00015	CcSEcCtD
Imatinib—Urticaria—Epirubicin—pancreatic cancer	2.61e-05	0.000149	CcSEcCtD
Imatinib—Constipation—Doxorubicin—pancreatic cancer	2.6e-05	0.000149	CcSEcCtD
Imatinib—Pain—Doxorubicin—pancreatic cancer	2.6e-05	0.000149	CcSEcCtD
Imatinib—Abdominal pain—Epirubicin—pancreatic cancer	2.59e-05	0.000149	CcSEcCtD
Imatinib—Body temperature increased—Epirubicin—pancreatic cancer	2.59e-05	0.000149	CcSEcCtD
Imatinib—Feeling abnormal—Doxorubicin—pancreatic cancer	2.5e-05	0.000143	CcSEcCtD
Imatinib—Gastrointestinal pain—Doxorubicin—pancreatic cancer	2.48e-05	0.000142	CcSEcCtD
Imatinib—Hypersensitivity—Epirubicin—pancreatic cancer	2.42e-05	0.000139	CcSEcCtD
Imatinib—Urticaria—Doxorubicin—pancreatic cancer	2.41e-05	0.000138	CcSEcCtD
Imatinib—Abdominal pain—Doxorubicin—pancreatic cancer	2.4e-05	0.000138	CcSEcCtD
Imatinib—Body temperature increased—Doxorubicin—pancreatic cancer	2.4e-05	0.000138	CcSEcCtD
Imatinib—Asthenia—Epirubicin—pancreatic cancer	2.35e-05	0.000135	CcSEcCtD
Imatinib—Pruritus—Epirubicin—pancreatic cancer	2.32e-05	0.000133	CcSEcCtD
Imatinib—Diarrhoea—Epirubicin—pancreatic cancer	2.24e-05	0.000129	CcSEcCtD
Imatinib—Hypersensitivity—Doxorubicin—pancreatic cancer	2.24e-05	0.000128	CcSEcCtD
Imatinib—Asthenia—Doxorubicin—pancreatic cancer	2.18e-05	0.000125	CcSEcCtD
Imatinib—Dizziness—Epirubicin—pancreatic cancer	2.17e-05	0.000124	CcSEcCtD
Imatinib—Pruritus—Doxorubicin—pancreatic cancer	2.15e-05	0.000123	CcSEcCtD
Imatinib—Vomiting—Epirubicin—pancreatic cancer	2.09e-05	0.00012	CcSEcCtD
Imatinib—Diarrhoea—Doxorubicin—pancreatic cancer	2.08e-05	0.000119	CcSEcCtD
Imatinib—Rash—Epirubicin—pancreatic cancer	2.07e-05	0.000119	CcSEcCtD
Imatinib—Dermatitis—Epirubicin—pancreatic cancer	2.07e-05	0.000119	CcSEcCtD
Imatinib—Headache—Epirubicin—pancreatic cancer	2.05e-05	0.000118	CcSEcCtD
Imatinib—Dizziness—Doxorubicin—pancreatic cancer	2.01e-05	0.000115	CcSEcCtD
Imatinib—Nausea—Epirubicin—pancreatic cancer	1.95e-05	0.000112	CcSEcCtD
Imatinib—Vomiting—Doxorubicin—pancreatic cancer	1.93e-05	0.000111	CcSEcCtD
Imatinib—Rash—Doxorubicin—pancreatic cancer	1.91e-05	0.00011	CcSEcCtD
Imatinib—Dermatitis—Doxorubicin—pancreatic cancer	1.91e-05	0.00011	CcSEcCtD
Imatinib—Headache—Doxorubicin—pancreatic cancer	1.9e-05	0.000109	CcSEcCtD
Imatinib—Nausea—Doxorubicin—pancreatic cancer	1.8e-05	0.000103	CcSEcCtD
Imatinib—PDGFRB—Disease—TGFB1—pancreatic cancer	3.16e-06	3.15e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—HRAS—pancreatic cancer	3.16e-06	3.15e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CASP3—pancreatic cancer	3.16e-06	3.15e-05	CbGpPWpGaD
Imatinib—KIT—Disease—PIK3CA—pancreatic cancer	3.16e-06	3.15e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—TYMS—pancreatic cancer	3.15e-06	3.14e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MMP9—pancreatic cancer	3.15e-06	3.14e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—AKT1—pancreatic cancer	3.15e-06	3.14e-05	CbGpPWpGaD
Imatinib—LCK—Disease—CTNNB1—pancreatic cancer	3.14e-06	3.13e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TGFB1—pancreatic cancer	3.13e-06	3.12e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PTEN—pancreatic cancer	3.13e-06	3.12e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—EGFR—pancreatic cancer	3.1e-06	3.09e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—KRAS—pancreatic cancer	3.09e-06	3.08e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PIK3CB—pancreatic cancer	3.09e-06	3.08e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	3.09e-06	3.08e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—SRC—pancreatic cancer	3.07e-06	3.06e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CCND1—pancreatic cancer	3.07e-06	3.06e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PTEN—pancreatic cancer	3.06e-06	3.05e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CTNNB1—pancreatic cancer	3.04e-06	3.03e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PIK3CD—pancreatic cancer	3.04e-06	3.03e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GLP1R—pancreatic cancer	3.04e-06	3.03e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—STK11—pancreatic cancer	3.03e-06	3.02e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—PIK3CA—pancreatic cancer	3.02e-06	3.01e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—STK11—pancreatic cancer	3e-06	2.99e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HRAS—pancreatic cancer	2.99e-06	2.98e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—DPYD—pancreatic cancer	2.99e-06	2.98e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—PIK3CA—pancreatic cancer	2.99e-06	2.98e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MMP9—pancreatic cancer	2.98e-06	2.97e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—APOE—pancreatic cancer	2.98e-06	2.97e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CXCL8—pancreatic cancer	2.97e-06	2.96e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—STAT3—pancreatic cancer	2.97e-06	2.96e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PTEN—pancreatic cancer	2.97e-06	2.96e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—NRAS—pancreatic cancer	2.96e-06	2.95e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—KRAS—pancreatic cancer	2.93e-06	2.92e-05	CbGpPWpGaD
Imatinib—KIT—Disease—HRAS—pancreatic cancer	2.92e-06	2.91e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TP53—pancreatic cancer	2.92e-06	2.91e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—PIK3CA—pancreatic cancer	2.91e-06	2.91e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—SRC—pancreatic cancer	2.9e-06	2.9e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—KRAS—pancreatic cancer	2.9e-06	2.89e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PIK3CB—pancreatic cancer	2.87e-06	2.86e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PIK3CB—pancreatic cancer	2.85e-06	2.84e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTGS2—pancreatic cancer	2.85e-06	2.84e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CD—pancreatic cancer	2.85e-06	2.84e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CD44—pancreatic cancer	2.84e-06	2.84e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PIK3CB—pancreatic cancer	2.84e-06	2.84e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CASP3—pancreatic cancer	2.84e-06	2.83e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—PIK3CA—pancreatic cancer	2.84e-06	2.83e-05	CbGpPWpGaD
Imatinib—LCK—Disease—SRC—pancreatic cancer	2.84e-06	2.83e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	2.83e-06	2.83e-05	CbGpPWpGaD
Imatinib—CA9—Metabolism—AKT1—pancreatic cancer	2.83e-06	2.82e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—TYMS—pancreatic cancer	2.83e-06	2.82e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—VEGFA—pancreatic cancer	2.83e-06	2.82e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTGS2—pancreatic cancer	2.82e-06	2.81e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTGS2—pancreatic cancer	2.82e-06	2.81e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.82e-06	2.81e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—STAT3—pancreatic cancer	2.8e-06	2.79e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—NRAS—pancreatic cancer	2.79e-06	2.79e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—AKT1—pancreatic cancer	2.79e-06	2.78e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—HRAS—pancreatic cancer	2.79e-06	2.78e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.79e-06	2.78e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CCND1—pancreatic cancer	2.77e-06	2.76e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—HRAS—pancreatic cancer	2.76e-06	2.75e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—TYMS—pancreatic cancer	2.76e-06	2.75e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PIK3CB—pancreatic cancer	2.76e-06	2.75e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.76e-06	2.75e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—SRC—pancreatic cancer	2.75e-06	2.74e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CTNNB1—pancreatic cancer	2.74e-06	2.73e-05	CbGpPWpGaD
Imatinib—LCK—Disease—STAT3—pancreatic cancer	2.74e-06	2.73e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTGS2—pancreatic cancer	2.74e-06	2.73e-05	CbGpPWpGaD
Imatinib—LCK—Disease—NRAS—pancreatic cancer	2.73e-06	2.72e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GCG—pancreatic cancer	2.73e-06	2.72e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HRAS—pancreatic cancer	2.7e-06	2.69e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—EGFR—pancreatic cancer	2.7e-06	2.69e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—PIK3CA—pancreatic cancer	2.69e-06	2.68e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CG—pancreatic cancer	2.69e-06	2.68e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MMP9—pancreatic cancer	2.69e-06	2.68e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—VEGFA—pancreatic cancer	2.68e-06	2.67e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PTEN—pancreatic cancer	2.67e-06	2.66e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—PIK3CA—pancreatic cancer	2.67e-06	2.66e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—STAT3—pancreatic cancer	2.65e-06	2.64e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PIK3CB—pancreatic cancer	2.65e-06	2.64e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—NRAS—pancreatic cancer	2.65e-06	2.64e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—AKT1—pancreatic cancer	2.64e-06	2.63e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—HRAS—pancreatic cancer	2.63e-06	2.62e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTGS2—pancreatic cancer	2.63e-06	2.62e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—TYMS—pancreatic cancer	2.6e-06	2.6e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MYC—pancreatic cancer	2.6e-06	2.59e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TGFB1—pancreatic cancer	2.6e-06	2.59e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PPARG—pancreatic cancer	2.59e-06	2.59e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—TYMS—pancreatic cancer	2.58e-06	2.57e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—pancreatic cancer	2.58e-06	2.57e-05	CbGpPWpGaD
Imatinib—KIT—Disease—AKT1—pancreatic cancer	2.58e-06	2.57e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—APOE—pancreatic cancer	2.56e-06	2.56e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—STK11—pancreatic cancer	2.56e-06	2.56e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—EGFR—pancreatic cancer	2.55e-06	2.54e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—KRAS—pancreatic cancer	2.55e-06	2.54e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MYC—pancreatic cancer	2.54e-06	2.54e-05	CbGpPWpGaD
Imatinib—LCK—Disease—TGFB1—pancreatic cancer	2.54e-06	2.53e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—HRAS—pancreatic cancer	2.49e-06	2.48e-05	CbGpPWpGaD
Imatinib—LCK—Disease—EGFR—pancreatic cancer	2.49e-06	2.48e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTEN—pancreatic cancer	2.48e-06	2.48e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CB—pancreatic cancer	2.48e-06	2.47e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—SRC—pancreatic cancer	2.48e-06	2.47e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—HRAS—pancreatic cancer	2.47e-06	2.46e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MYC—pancreatic cancer	2.46e-06	2.46e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—AKT1—pancreatic cancer	2.46e-06	2.46e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTEN—pancreatic cancer	2.46e-06	2.45e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TGFB1—pancreatic cancer	2.46e-06	2.45e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTEN—pancreatic cancer	2.46e-06	2.45e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—AKT1—pancreatic cancer	2.44e-06	2.43e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.43e-06	2.42e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—VEGFA—pancreatic cancer	2.41e-06	2.4e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—EGFR—pancreatic cancer	2.41e-06	2.4e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.41e-06	2.4e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—KRAS—pancreatic cancer	2.41e-06	2.4e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—STAT3—pancreatic cancer	2.39e-06	2.38e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTEN—pancreatic cancer	2.39e-06	2.38e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CXCL8—pancreatic cancer	2.38e-06	2.38e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—NRAS—pancreatic cancer	2.38e-06	2.38e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—AKT1—pancreatic cancer	2.38e-06	2.37e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CD—pancreatic cancer	2.36e-06	2.35e-05	CbGpPWpGaD
Imatinib—LCK—Disease—KRAS—pancreatic cancer	2.35e-06	2.34e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—PIK3CA—pancreatic cancer	2.34e-06	2.33e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—AKT1—pancreatic cancer	2.32e-06	2.31e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CG—pancreatic cancer	2.31e-06	2.31e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—APOE—pancreatic cancer	2.3e-06	2.29e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTEN—pancreatic cancer	2.29e-06	2.28e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CASP3—pancreatic cancer	2.28e-06	2.27e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—KRAS—pancreatic cancer	2.28e-06	2.27e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—APOE—pancreatic cancer	2.25e-06	2.24e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PPARG—pancreatic cancer	2.23e-06	2.23e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCND1—pancreatic cancer	2.22e-06	2.21e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MYC—pancreatic cancer	2.22e-06	2.21e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TGFB1—pancreatic cancer	2.21e-06	2.21e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PIK3CA—pancreatic cancer	2.21e-06	2.2e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—TYMS—pancreatic cancer	2.21e-06	2.2e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CTNNB1—pancreatic cancer	2.2e-06	2.19e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—AKT1—pancreatic cancer	2.2e-06	2.19e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CD44—pancreatic cancer	2.2e-06	2.19e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.18e-06	2.17e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—AKT1—pancreatic cancer	2.18e-06	2.17e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EGFR—pancreatic cancer	2.17e-06	2.16e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—HRAS—pancreatic cancer	2.16e-06	2.16e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PIK3CA—pancreatic cancer	2.16e-06	2.15e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MMP9—pancreatic cancer	2.16e-06	2.15e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PTEN—pancreatic cancer	2.14e-06	2.14e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—pancreatic cancer	2.14e-06	2.13e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—APOE—pancreatic cancer	2.12e-06	2.11e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GCG—pancreatic cancer	2.1e-06	2.1e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—APOE—pancreatic cancer	2.1e-06	2.09e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PIK3CA—pancreatic cancer	2.09e-06	2.09e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	2.08e-06	2.07e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	2.06e-06	2.05e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—KRAS—pancreatic cancer	2.05e-06	2.04e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—HRAS—pancreatic cancer	2.04e-06	2.04e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTGS2—pancreatic cancer	2.04e-06	2.03e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CD—pancreatic cancer	2.03e-06	2.03e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CG—pancreatic cancer	2.03e-06	2.02e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—pancreatic cancer	2.02e-06	2.02e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PPARG—pancreatic cancer	2.01e-06	2e-05	CbGpPWpGaD
Imatinib—LCK—Disease—HRAS—pancreatic cancer	2e-06	1.99e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SRC—pancreatic cancer	1.99e-06	1.98e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.99e-06	1.98e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—STK11—pancreatic cancer	1.98e-06	1.97e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PPARG—pancreatic cancer	1.96e-06	1.95e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—VEGFA—pancreatic cancer	1.94e-06	1.93e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—HRAS—pancreatic cancer	1.94e-06	1.93e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—STAT3—pancreatic cancer	1.92e-06	1.91e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NRAS—pancreatic cancer	1.91e-06	1.91e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	1.91e-06	1.9e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—AKT1—pancreatic cancer	1.91e-06	1.9e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	1.89e-06	1.89e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PIK3CA—pancreatic cancer	1.88e-06	1.88e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PPARG—pancreatic cancer	1.84e-06	1.84e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PPARG—pancreatic cancer	1.83e-06	1.82e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	1.83e-06	1.82e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—pancreatic cancer	1.82e-06	1.82e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—AKT1—pancreatic cancer	1.81e-06	1.8e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—APOE—pancreatic cancer	1.79e-06	1.79e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CD—pancreatic cancer	1.78e-06	1.78e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MYC—pancreatic cancer	1.78e-06	1.78e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTEN—pancreatic cancer	1.78e-06	1.77e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TGFB1—pancreatic cancer	1.78e-06	1.77e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CB—pancreatic cancer	1.77e-06	1.77e-05	CbGpPWpGaD
Imatinib—LCK—Disease—AKT1—pancreatic cancer	1.76e-06	1.76e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTGS2—pancreatic cancer	1.76e-06	1.75e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PIK3CA—pancreatic cancer	1.75e-06	1.75e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—HRAS—pancreatic cancer	1.74e-06	1.74e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EGFR—pancreatic cancer	1.74e-06	1.74e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PIK3CA—pancreatic cancer	1.74e-06	1.73e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PIK3CA—pancreatic cancer	1.73e-06	1.73e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—AKT1—pancreatic cancer	1.71e-06	1.7e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—TYMS—pancreatic cancer	1.7e-06	1.7e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.7e-06	1.69e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PIK3CA—pancreatic cancer	1.68e-06	1.68e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	1.68e-06	1.67e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	1.67e-06	1.66e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KRAS—pancreatic cancer	1.65e-06	1.64e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	1.62e-06	1.61e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PIK3CA—pancreatic cancer	1.62e-06	1.61e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	1.59e-06	1.59e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTGS2—pancreatic cancer	1.58e-06	1.57e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PPARG—pancreatic cancer	1.56e-06	1.56e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CB—pancreatic cancer	1.55e-06	1.55e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTGS2—pancreatic cancer	1.54e-06	1.53e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—AKT1—pancreatic cancer	1.54e-06	1.53e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTEN—pancreatic cancer	1.53e-06	1.53e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CA—pancreatic cancer	1.51e-06	1.51e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	1.46e-06	1.46e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—pancreatic cancer	1.46e-06	1.46e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	1.45e-06	1.45e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTGS2—pancreatic cancer	1.45e-06	1.45e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTGS2—pancreatic cancer	1.44e-06	1.43e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—AKT1—pancreatic cancer	1.43e-06	1.43e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	1.42e-06	1.42e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—AKT1—pancreatic cancer	1.42e-06	1.41e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—AKT1—pancreatic cancer	1.42e-06	1.41e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—HRAS—pancreatic cancer	1.4e-06	1.39e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—APOE—pancreatic cancer	1.38e-06	1.38e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTEN—pancreatic cancer	1.38e-06	1.37e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—AKT1—pancreatic cancer	1.38e-06	1.37e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTEN—pancreatic cancer	1.34e-06	1.34e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—AKT1—pancreatic cancer	1.32e-06	1.32e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTEN—pancreatic cancer	1.27e-06	1.26e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	1.26e-06	1.25e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTEN—pancreatic cancer	1.25e-06	1.25e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	1.25e-06	1.25e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	1.24e-06	1.24e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AKT1—pancreatic cancer	1.24e-06	1.23e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTGS2—pancreatic cancer	1.23e-06	1.23e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PPARG—pancreatic cancer	1.21e-06	1.2e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	1.1e-06	1.09e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CA—pancreatic cancer	1.08e-06	1.08e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTEN—pancreatic cancer	1.07e-06	1.07e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—AKT1—pancreatic cancer	1.03e-06	1.02e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	9.71e-07	9.67e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	9.57e-07	9.54e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTGS2—pancreatic cancer	9.49e-07	9.46e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CA—pancreatic cancer	9.47e-07	9.44e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	8.93e-07	8.9e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	8.85e-07	8.82e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—AKT1—pancreatic cancer	8.83e-07	8.8e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTEN—pancreatic cancer	8.27e-07	8.25e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—AKT1—pancreatic cancer	7.93e-07	7.9e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—AKT1—pancreatic cancer	7.74e-07	7.71e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	7.56e-07	7.54e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AKT1—pancreatic cancer	7.29e-07	7.27e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AKT1—pancreatic cancer	7.23e-07	7.21e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AKT1—pancreatic cancer	6.18e-07	6.16e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	5.84e-07	5.82e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AKT1—pancreatic cancer	4.77e-07	4.75e-06	CbGpPWpGaD
